1. Home
  2. CALY vs MESO Comparison

CALY vs MESO Comparison

Compare CALY & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CALY

Callaway Golf Company

N/A

Current Price

$13.98

Market Cap

2.6B

Sector

N/A

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.70

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CALY
MESO
Founded
1982
2004
Country
United States
Australia
Employees
28000
81
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CALY
MESO
Price
$13.98
$14.70
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$16.50
N/A
AVG Volume (30 Days)
2.0M
262.6K
Earning Date
05-07-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.23
$644.56
Revenue Next Year
N/A
$38.63
P/E Ratio
$64.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.26
$9.88
52 Week High
$16.65
$21.50

Technical Indicators

Market Signals
Indicator
CALY
MESO
Relative Strength Index (RSI) 50.44 47.16
Support Level $13.18 $14.44
Resistance Level $13.96 $16.77
Average True Range (ATR) 0.48 0.59
MACD 0.08 0.07
Stochastic Oscillator 44.83 41.47

Price Performance

Historical Comparison
CALY
MESO

About CALY Callaway Golf Company

Callaway Golf Co is a golf equipment, gear and apparel company with a portfolio of world-wide brands, including Callaway Golf, Odyssey, TravisMathew, and OGIO. Callaway designs, manufactures, and sells high-performance golf clubs, golf balls, apparel, bags, and other accessories-setting the standard for performance in the game of golf. The company has two operating and reportable business segments: Golf Equipment and Apparel, Gear and Other. Geographically, the company operates in United States, Europe, Asia, and Rest of World, of which it derives maximum revenue from United States.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: